Sodium-retaining activity of some natural and synthetic 21-deoxysteroids
The effect of progesterone and six other C21 -deoxysteroids on renal sodium retention by male adrenaleotomized rats was compared with the effect exerted by the natural corticoids aldosterone, 11-deoxycorticosterone, and corticosterone. Steroids were active in the following order: aldosterone > 11...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
1995
|
| Materias: | |
| Acceso en línea: | Registro en Scopus Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 05806caa a22010337a 4500 | ||
|---|---|---|---|
| 001 | PAPER-19002 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205022.0 | ||
| 008 | 190411s1995 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-0028956967 | |
| 024 | 7 | |2 cas |a 11beta,17beta dihydroxy 6 methyl 17alpha (1 propynyl)androsta 1,4,6 trien 3 one, 74915-64-3; 5alpha pregnane 3,20 dione, 566-65-4; aldosterone, 52-39-1, 6251-69-0; corticosterone, 50-22-6; deoxycorticosterone, 64-85-7; pregnanedione, 33041-33-7, 7350-00-7; progesterone, 57-83-0; transcortin, 9013-32-5; 11,19-oxidoprogesterone, 1913-28-6; Aldosterone, 52-39-1; Desoxycorticosterone, 64-85-7; Potassium, 7440-09-7; Progesterone, 57-83-0; Receptors, Steroid; Sodium, 7440-23-5; Steroids; Tritium, 10028-17-8 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a MOPMA | ||
| 100 | 1 | |a Burton, G. | |
| 245 | 1 | 0 | |a Sodium-retaining activity of some natural and synthetic 21-deoxysteroids |
| 260 | |c 1995 | ||
| 270 | 1 | 0 | |m Burton, G.; Departamento de Quimica Organica, Facultad Ciencias Exactas/Naturales, Ciudad Universitaria, 1428 Buenos Aires, Argentina |
| 506 | |2 openaire |e Política editorial | ||
| 520 | 3 | |a The effect of progesterone and six other C21 -deoxysteroids on renal sodium retention by male adrenaleotomized rats was compared with the effect exerted by the natural corticoids aldosterone, 11-deoxycorticosterone, and corticosterone. Steroids were active in the following order: aldosterone > 11,19-oxidoprogesterone > 5αH-3,20-pregnanedione ≥ 5βH-3,20-pregnanedione > progesterone = 11-ketoprogesterone > 6,19-oxidoprogesterone = 11-keto- 6,19-oxidoprogesterone ≥ corticosterone. All C21-deoxysteroids, except 11,19-oxidoprogesterone, exhibited parabolic log dose-response functions, indicating an effect that opposes renal sodium retention at high doses. 11,19-Oxidoprogesterone and the natural corticoids exhibited normal, exponential, log dose-response curves. Diverse geometric parameters related to molecular planarity were calculated and their correlation with biopharmacological properties was attempted. The best linear regression was obtained for correlation of the concavity of log dose-response parabolas (second-order coefficients) of C21-deoxysteroids with the C3=O/ring D angle of these molecules. A good linear regression could also be obtained for correlation of the affinity of C21-deoxysteroids, except 11,19- oxidoprogesterone, for purified type I mineralocorticoid receptors with those angles. The latter correlation deteriorated upon incorporation of the affinity data for the three natural corticoids, due to similar affinities of these hormones for type I mineralocorticoid receptors, but could be restored when the binding data for the unpurified, corticosterone-binding globulin- containing stage of the receptors were considered. In vivo binding data followed the same trend as that for unpurified receptors. |l eng | |
| 593 | |a Departamento de Quimica Organica, Facultad Ciencias Exactas/Naturales, Ciudad Universitaria, 1428 Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a 11,19 OXIDOPROGESTERONE |
| 690 | 1 | 0 | |a 11BETA,17BETA DIHYDROXY 6 METHYL 17ALPHA (1 PROPYNYL)ANDROSTA 1,4,6 TRIEN 3 ONE |
| 690 | 1 | 0 | |a 21 DEOXYCORTICOSTERONE |
| 690 | 1 | 0 | |a 5ALPHA PREGNANE 3,20 DIONE |
| 690 | 1 | 0 | |a 6,19 OXIDO 11 OXOPROGESTERONE |
| 690 | 1 | 0 | |a 6,19 OXIDOPROGESTERONE |
| 690 | 1 | 0 | |a ALDOSTERONE |
| 690 | 1 | 0 | |a CORTICOSTERONE |
| 690 | 1 | 0 | |a DEOXYCORTICOSTERONE |
| 690 | 1 | 0 | |a MINERALOCORTICOID RECEPTOR |
| 690 | 1 | 0 | |a PREGNANEDIONE |
| 690 | 1 | 0 | |a PROGESTERONE |
| 690 | 1 | 0 | |a PROGESTERONE DERIVATIVE |
| 690 | 1 | 0 | |a TRANSCORTIN |
| 690 | 1 | 0 | |a UNCLASSIFIED DRUG |
| 690 | 1 | 0 | |a ADRENALECTOMY |
| 690 | 1 | 0 | |a ANIMAL EXPERIMENT |
| 690 | 1 | 0 | |a ANIMAL TISSUE |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a DOSE RESPONSE |
| 690 | 1 | 0 | |a DRUG CONFORMATION |
| 690 | 1 | 0 | |a DRUG HALF LIFE |
| 690 | 1 | 0 | |a INTRAMUSCULAR DRUG ADMINISTRATION |
| 690 | 1 | 0 | |a INTRAPERITONEAL DRUG ADMINISTRATION |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a POTASSIUM URINE LEVEL |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a RAT |
| 690 | 1 | 0 | |a RECEPTOR AFFINITY |
| 690 | 1 | 0 | |a SODIUM RETENTION |
| 690 | 1 | 0 | |a SODIUM URINE LEVEL |
| 690 | 1 | 0 | |a SUBCUTANEOUS DRUG ADMINISTRATION |
| 690 | 1 | 0 | |a ADRENAL GLANDS |
| 690 | 1 | 0 | |a ADRENALECTOMY |
| 690 | 1 | 0 | |a ALDOSTERONE |
| 690 | 1 | 0 | |a ANIMAL |
| 690 | 1 | 0 | |a COMPARATIVE STUDY |
| 690 | 1 | 0 | |a CYTOSOL |
| 690 | 1 | 0 | |a DESOXYCORTICOSTERONE |
| 690 | 1 | 0 | |a HALF-LIFE |
| 690 | 1 | 0 | |a KIDNEY |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a MOLECULAR CONFORMATION |
| 690 | 1 | 0 | |a POTASSIUM |
| 690 | 1 | 0 | |a PROGESTERONE |
| 690 | 1 | 0 | |a RATS |
| 690 | 1 | 0 | |a RATS, SPRAGUE-DAWLEY |
| 690 | 1 | 0 | |a RECEPTORS, STEROID |
| 690 | 1 | 0 | |a SODIUM |
| 690 | 1 | 0 | |a STEROIDS |
| 690 | 1 | 0 | |a SUPPORT, NON-U.S. GOV'T |
| 690 | 1 | 0 | |a TRITIUM |
| 653 | 0 | 0 | |a ru 28362, roussel uclaf, France |
| 700 | 1 | |a Galigniana, M. | |
| 700 | 1 | |a De Lavallaz, S. | |
| 700 | 1 | |a Brachet-Cota, A.L. | |
| 700 | 1 | |a Sproviero, E.M. | |
| 700 | 1 | |a Ghini, A.A. | |
| 700 | 1 | |a Lantos, C.P. | |
| 700 | 1 | |a Damasco, M.C. | |
| 773 | 0 | |d 1995 |g v. 47 |h pp. 535-543 |k n. 3 |p MOL. PHARMACOL. |x 0026895X |t Molecular Pharmacology | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028956967&partnerID=40&md5=bd2fe01a3ad38bded5583a82505811e6 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_0026895X_v47_n3_p535_Burton |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0026895X_v47_n3_p535_Burton |y Registro en la Biblioteca Digital |
| 961 | |a paper_0026895X_v47_n3_p535_Burton |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 79955 | ||